Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotech VaxDome Inc. to bring its novel antigen-agnostic antiviral-vaccine hybrid candidates into clinical trials. Under the agreement, Matica Bio will provide process development, analytical development, and the production of both non-GMP and cGMP clinical materials.

The project centers on VaxDome's unique approach to broad protection against diverse known / unknown viruses as well as lung cancer by rapid transformation of a selected influenza virus strain into a safe, intranasally delivered, antigen-agnostic antiviral / vaccine hybrid (zIFV). Matica Bio will execute the work at its purpose-built facility in College Station, Texas.

This collaboration highlights Matica Bio's role as a trusted partner for complex, next-generation viral programs. With deep expertise across multiple virus and cell modalities including AAV, lentivirus, and oncolytic viruses Matica Bio brings specialized technical precision to VaxDome's hybrid platform. By integrating advanced single-use technologies and inline process monitoring at its Texas site, Matica Bio delivers rapid, predictable scaling from early-stage design straight through to clinical production.

"VaxDome's hybrid technology is a really fresh take on how we can treat and prevent viral infections in a wide variety of disease settings including flu," said Paul Kim, CEO of Matica Bio. "Our Texas site has the right systems, advanced cell line technologies, and specialized technical staff to take this project from early process development all the way through to manufacturing the actual batches for clinical trials."

"We chose Matica Bio because they can handle every step of the manufacturing process under one roof," said De-chu Christopher Tang, PhD, CEO of VaxDome. "Having development, analytical testing, and GMP production fully integrated at their Texas facility gives our team complete peace of mind as we move this candidate toward the clinic."

Matica Bio will manage the entire technical transition between phases, ensuring the final vaccine meets all safety, purity, and regulatory standards.